Compare VCIG & AZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VCIG | AZTR |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0M | 3.2M |
| IPO Year | 2023 | 2023 |
| Metric | VCIG | AZTR |
|---|---|---|
| Price | $0.84 | $0.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 1.8M | 1.1M |
| Earning Date | 05-08-2026 | 02-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.98 | N/A |
| Revenue | ★ $32,903,041.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.87 | ★ N/A |
| Revenue Growth | ★ 24.77 | N/A |
| 52 Week Low | $0.51 | $0.26 |
| 52 Week High | $978.00 | $3.92 |
| Indicator | VCIG | AZTR |
|---|---|---|
| Relative Strength Index (RSI) | 49.53 | 52.27 |
| Support Level | $0.73 | $0.26 |
| Resistance Level | $1.14 | $0.31 |
| Average True Range (ATR) | 0.13 | 0.03 |
| MACD | 0.07 | 0.01 |
| Stochastic Oscillator | 53.04 | 64.28 |
VCI Global Ltd is a holding company. The principal activities of the Company and its subsidiaries are the provision of business Strategy consultancy and technology development. The firm organized its consulting services into three main segments: Business Strategy Consultancy; Technology development, solutions and consultancy; and Others. It derives the majority of its revenue from the Business Strategy Consultancy segment, which focuses on listing solutions, investor relations, and boardroom strategies consultancy.
Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.